Ratios

		vs industry	vs history
P/B	4.53	CCXI's P/B is ranked higher than 57% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 3.80 vs. CCXI: 4.53 )	CCXI' s 10-Year P/B Range Min: 2.46   Max: 4.96 Current: 4.53 2.46 4.96
P/S	80.06	CCXI's P/S is ranked lower than 58% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 6.90 vs. CCXI: 80.06 )	CCXI' s 10-Year P/S Range Min: 68.59   Max: 576.33 Current: 80.06 68.59 576.33
EV-to-EBIT	-12.34	CCXI's EV-to-EBIT is ranked higher than 72% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 14.61 vs. CCXI: -12.34 )	CCXI' s 10-Year EV-to-EBIT Range Min: 46.6   Max: 97 Current: -12.34 46.6 97

Valuation & Return

		vs industry	vs history
Price/Net Cash	5.6	CCXI's Price/Net Cash is ranked higher than 65% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 8.80 vs. CCXI: 5.6 )	CCXI' s 10-Year Price/Net Cash Range Min: 4.3   Max: 4.3 Current: 5.6
Price/Net Current Asset Value	141.3	CCXI's Price/Net Current Asset Value is ranked lower than 61% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 32.60 vs. CCXI: 141.3 )	CCXI' s 10-Year Price/Net Current Asset Value Range Min: 109.4   Max: 109.4 Current: 141.3
Price/Tangible Book	4.5	CCXI's Price/Tangible Book is ranked lower than 93% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 4.70 vs. CCXI: 4.5 )	CCXI' s 10-Year Price/Tangible Book Range Min: 3.5   Max: 3.5 Current: 4.5
Price/Median PS Value	0.8	CCXI's Price/Median PS Value is ranked lower than 93% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 0.90 vs. CCXI: 0.8 )	CCXI' s 10-Year Price/Median PS Value Range Min: 0.6   Max: 0.6 Current: 0.8

Business Description

Chemocentryx, Inc. is incorporated in the state of Delaware. The company commenced operations in 1997. It is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The company's approach has been to target the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development, and expects to advance one additional drug candidate into clinical development in 2012. Two of these drug candidates are wholly owned and are being developed independently by the company while four are subject to its collaboration agreement with Glaxo Group Limited, or GSK, an affiliate of GlaxoSmithKline. Under this agreement, GSK has exercised its option to obtain an exclusive license to further develop and commercialize Traficet-EN, is currently evaluating its option to CCX354, and will have similar option rights to CCX168 and CCX832 if the company establishs clinical proof-of-concept. All of its drug candidates have been internally discovered and include: Traficet-EN (CCX282 or GSK'786) — Its advanced drug candidate, currently in three pivotal Phase III clinical trials being conducted by its partner GSK for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 —an independent drug candidate successfully completed a Phase II clinical trial in type 2 diabetics and is currently in two Phase II clinical trials in patients with diabetic nephropathy, a form of kidney disease; CCX354 — Successfully completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis, or RA, and the company expects GSK's option decision by the end of 2011; CCX168 — Currently in a Phase II proof-of-concept clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA-associated vasculitis, or AAV, and is subject to GSK's option; CCX832 — Recently completed a Phase I clinical trial. Subject to further discussion with GSK, expected to enter a Phase II proof-of-concept clinical trial for the treatment of skin inflammation, and is subject to GSK's option; and CCX662 — its independent drug candidate for the treatment of glioblastoma multiforme, or GBM, is expected to enter a Phase I clinical trial in the second half of 2012. The company's strategies includes the following: collaborate with its partner GSK in the Phase III clinical development and commercialization of Traficet-EN; Forward integrate into a commercial biopharmaceutical company by driving the development and commercialization of it independent drug candidate, CCX140; Expanding its clinical stage portfolio of internally discovered, independent drug candidates; Commercializing drug candidates in specialty markets in North America and par
Company Website
SEC Reports

Industry:	Biotechnology
Compare:
Traded in other countries:	2CX.Germany

» More Articles for CCXI

Headlines

Articles On GuruFocus.com

Personalized Checklist